Sale of Ordinary Shares in Quantum

Quantum Pharma Plc

("Quantum" or the "Group")

Sale of Ordinary Shares in Quantum

Quantum Pharma Plc (AIM: QP.), a service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, has been informed today that LDC (Managers) Limited ("LDC"), acting as investment manager on behalf of Lloyds Development Capital (Holdings) Limited, OBS 2009 LP and LDC Opportunity Club 2009, has sold an aggregate of 8,800,000 ordinary shares today representing c.7.04 per cent. of the total number of voting rights in the Group (the "Transaction"). Zeus Capital has given its consent to release these shares from the lock-in agreed at the time of the Group's Admission to AIM due to the high level of institutional demand for Quantum's shares following the Group's recent annual results announcement. The ordinary shares have been successfully placed today by Zeus Capital to a small number of existing shareholders.

Following the Transaction, the funds managed by LDC continue to hold a non-discloseable interest in the ordinary shares and the total voting rights in Quantum. These shares remain subject to a lock-in which expires on 11 June 2015.

Andrew Scaife, CEO of Quantum Pharma, commented: "Following strong demand from institutional investors at the time of the Group's final results roadshow in late May, we are pleased that, working in conjunction with our broker, we have been able to successfully satisfy this demand through the desire of LDC to reduce their holding to below 3%.

"LDC have played a pivotal role in the development of the Group since the MBO in 2009 and the Board joins me in thanking them for their support over the last six years. We welcome our new shareholders as we continue to make solid progress with our strategy as a quoted company."

- Ends -

For further information:

Media enquiries:

Notes to Editors

Quantum Pharma is a service-led, niche pharmaceutical manufacturer, developer and supplier to the retail pharmacy, pharmaceutical wholesale, hospital, homecare and care home markets. The Quantum Pharma Group operates through seven business units offering a portfolio of innovative and complementary products and services to providers in primary and secondary care.

Quantum Pharmaceutical manufactures and supplies specials and special obtains for the majority of large retail pharmacy chains in the UK, as well as large pharmaceutical wholesalers, hospitals and independent pharmacies. Specials are bespoke, non-licensed medicines which can be custom manufactured as a one-off or procured for individual patient needs where a clinician deems a patient requires a bespoke formulation for their treatment. The company can manufacture and supply bespoke medicines in as little as 15 hours and regularly services around 6,500 pharmacies across the UK with a choice of more than 22,000 specials or special obtains.

Quantum Aseptic Services manufactures aseptically prepared sterile intravenous products, either individually for named patients or in batches. Serving the hospital market (both NHS and private) and homecare patients, its unique, six-day-a-week, next morning (by 10.30am) compounding service enables many hospitals to offer chemotherapy treatment five days a week, unencumbered by the delays of aseptic production.

UL Medicines sources and supplies unlicensed imported medicines and bespoke specials to hospitals, community pharmacies and wholesalers in the UK and overseas. The company offers approximately 500 imported medicines sourced from more than 24 countries, as well as a specialist over-labelling service that translates accompanying local language patient documentation into English.

Biodose® is the only medicines delivery system that accommodates both liquid and solid medication, supporting medicines administration and adherence for 50,000 patients with complex medication regimes, their carers and clinicians. Building on its success, Biodose Connect®, due for launch in early 2016, incorporates telemedicines technology to provide live, remote monitoring and management of patient adherence to prevent avoidable and costly hospital admissions.

Biodose Services® provides pre-prepared medication regimes to care homes and delivery of medication to the home. Biodose Services is the UK's largest provider of the Biodose system and operates from a 7,600ft purpose-designed specialist pharmacy in West Yorkshire. The company also offers a range of homecare services to the NHS, private clinics and pharmaceutical companies including the Stork Fertility Service®, premium homecare for patients receiving fertility treatment.

Colonis is a product development business which takes niche pharmaceutical products through the regulatory pathway to achieve licensed and/or regulated product status. Colonis launched its first licensed product, Aviticol in December 2014. Colonis has also launched one regulated product and a second licensed product is being manufactured ready for launch. The company is currently working on a significant pipeline of approximately 60 products (SKUs) across a growing number of therapeutic areas, 10 of which have been submitted for approval to the MHRA.

Lamda is a full service contract development specialist with customers in the UK, Ireland, Germany, France, Italy, Sweden, Greece and Cyprus. As well as providing in-house development for the Colonis pipeline, Lamda provides a fully outsourced research and development service for pharmaceutical companies looking to develop pharmaceutical forms or to license medicinal products.

For further information, please visit www.quantumpharmagroup.com.